ESLAW Estrella Immunopharma, Inc. - Warrant
$0,11
Fiyat · May 15, 2026
Temel veriler itibarıyla Mar 18, 2026
52 Haftlık Aralık
$0–$0
56% of range
Analist Derecelendirmesi
—
Fiyat Hedefi
—
P/E (TTM)
—
ROE
158.7%
Net Kâr Marjı
—
ESLAW Hisse Senedi Özeti Fiyat, piyasa değeri, P/E, EPS, ROE, borç/öz sermaye, 52 haftalık aralık
Fiyat
$0.11
Piyasa Değeri
—
P/E (TTM)
—
EPS (TTM)
$-0.35
Gelir (TTM)
—
Temettü Verimi
—
ROE
158.7%
D/E Borç/Özsermaye
—
52 Haftlık Aralık
$0 – $0
ESLAW Hisse Senedi Fiyat Grafiği Teknik göstergeler ile günlük OHLCV — kaydır, yakınlaştır ve görünümünüzü özelleştirin
Configure
10 Yıllık Performans Gelir, net kar, marjlar ve EPS trendleri
Gelir ve Net Gelir
—
Hisse Başına Kâr
$-0.35
2023-06-30
→
2025-12-31
Serbest Nakit Akışı
—
Marjlar
—
Değerleme P/E, P/S, P/B, EV/EBITDA oranları — hisse senedi pahalı mı ucuz mu?
Metrik
5 Yıllık trend
ESLAW
Akran Ortalaması
Kârlılık Brüt, faaliyet ve net kâr marjları; ROE, ROA, ROIC
Metrik
5 Yıllık trend
ESLAW
Akran Ortalaması
ROA
-413.6%
—
ROE
158.7%
—
ROIC
126.0%
—
Finansal Sağlık Borç, likidite, solventlik — bilanço gücü
Metrik
5 Yıllık trend
ESLAW
Akran Ortalaması
Current Ratio (Cari Oran)
0.1
—
Quick Ratio (Cari Oran)
0.1
—
Büyüme Gelir, EPS ve net gelir büyümesi: YOY, 3 Yıllık CAGR, 5 Yıllık CAGR
Metrik
5 Yıllık trend
ESLAW
Akran Ortalaması
Sermaye Verimliliği Aktif devir hızı, stok devir hızı, alacak devir hızı
Metrik
5 Yıllık trend
ESLAW
Akran Ortalaması
Tüm Temeller Tüm metrikler yıla göre — gelir tablosu, bilanço, nakit akışı
Gelir Tablosu 13
| Metrik | Eğilim | 2025 | 2024 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|---|---|
| R&D Expense | $10M | · | $4M | $10M | · | · | |
| SG&A Expense | $3M | · | $3M | $663.2K | · | · | |
| Operating Expenses | $13M | · | $7M | $11M | · | · | |
| Operating Income | $-13M | · | $-7M | $-11M | $-2M | $-249.1K | |
| Interest Income | · | · | · | · | $654.1K | $1.4K | |
| Pretax Income | $-13M | · | $-7M | $-11M | $-915.5K | $-247.7K | |
| Income Tax | $838 | · | $1.6K | · | $80.6K | $0 | |
| Net Income | $-13M | · | $-7M | $-11M | $-996.1K | $-247.7K | |
| EPS (Basic) | $-0.35 | · | $-0.27 | $-36.35 | · | · | |
| EPS (Diluted) | $-0.35 | · | $-0.27 | $-36.35 | · | · | |
| Shares (Basic) | 36,820,810 | · | 27,103,964 | 305,748 | · | 1,179,328 | |
| Shares (Diluted) | 36,820,810 | · | 27,103,964 | 305,748 | · | 1,179,328 | |
| EBITDA | $-13M | · | · | · | $-2M | $-249.1K |
Bilanço 18
| Metrik | Eğilim | 2025 | 2024 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $1M | $916.9K | $4M | $2M | $40.8K | $478.9K | |
| Receivables | · | · | · | $273.1K | · | · | |
| Prepaid Expense | $292.7K | $723.9K | $288.8K | · | $11.6K | $137.2K | |
| Current Assets | $2M | $2M | $4M | $3M | $52.4K | $616.0K | |
| Total Assets | $3M | $3M | $4M | $3M | $10M | $46M | |
| Accounts Payable | · | · | · | · | $329.2K | $3.0K | |
| Accrued Liabilities | · | · | · | $116.5K | · | · | |
| Current Liabilities | $14M | $3M | $180.7K | $10M | $1M | $73.2K | |
| Deferred Tax | · | · | · | · | $29.5K | · | |
| Other Non-current Liabilities | · | · | · | $12.7K | · | · | |
| Total Liabilities | $14M | $3M | $180.7K | $10M | $3M | $2M | |
| Common Stock | $3.8K | $3.7K | $3.7K | $98 | $142 | $142 | |
| Paid-in Capital | $27M | $25M | $24M | $445.9K | · | · | |
| Retained Earnings | $-37M | $-24M | $-20M | $-12M | $-2M | $-1M | |
| Treasury Stock | $598.4K | $568.9K | $354.4K | · | · | · | |
| Stockholders' Equity | $-10M | $143.7K | $4M | $-12M | $-6M | $-1M | |
| Liabilities + Equity | $3M | $3M | $4M | $3M | $10M | $46M | |
| Shares Outstanding | · | 36,193,891 | 36,610,870 | 978,243 | 1,419,700 | 1,419,700 |
Nakit Akışı 9
| Metrik | Eğilim | 2025 | 2024 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|---|---|
| Stock-based Comp | $619.0K | · | $1M | $409.6K | · | · | |
| Deferred Tax | · | · | · | · | $29.5K | · | |
| Operating Cash Flow | $-2M | · | $-16M | $-1M | $-1M | $-316.2K | |
| Investing Cash Flow | · | · | $5M | $-273.1K | $36M | $-45M | |
| Stock Issued | $2M | · | · | · | · | $25.0K | |
| Net Stock Activity | $2M | · | · | · | · | $25.0K | |
| Financing Cash Flow | $2M | · | $13M | · | $-36M | $46M | |
| Net Change in Cash | · | · | · | · | $-438.1K | $478.9K | |
| Taxes Paid | $913 | · | $1.6K | · | · | · |
Kârlılık 3
| Metrik | Eğilim | 2025 | 2024 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|---|---|
| ROA | -413.6% | · | · | · | -3.6% | -1.1% | |
| ROE | 158.7% | · | · | · | 32.8% | 26.4% | |
| ROIC | 126.0% | · | · | · | 75.7% | 24.8% |
Likidite ve Solventlik 2
| Metrik | Eğilim | 2025 | 2024 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|---|---|
| Current Ratio | 0.1 | · | · | · | 0.0 | 8.4 | |
| Quick Ratio | 0.1 | · | · | · | 0.0 | 6.5 |
Değerleme (TTM) 1
| Metrik | Eğilim | 2025 | 2024 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|---|---|
| Net Income TTM | $-13M | · | $-7M | · | $-996.1K | $-247.7K |
Gelir Tablosu 13
| Metrik | Eğilim | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q1 2024 | Q4 2024 | Q3 2024 | Q2 2023 | Q1 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 | Q2 2022 | Q1 2022 | Q4 2021 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| R&D Expense | $25.4K | $4M | $5M | $1M | $3M | $4M | $25.0K | $75.5K | $483.5K | $3M | $3M | $3M | $3M | · | · | · | |
| SG&A Expense | $587.8K | $648.5K | $883.7K | $694.1K | $550.7K | $424.4K | $444.5K | $945.2K | $1M | $116.8K | $117.7K | $148.4K | $280.3K | · | · | · | |
| Operating Expenses | $613.2K | $5M | $6M | $2M | $3M | $4M | $469.5K | $1M | $2M | $3M | $3M | $3M | $3M | · | · | · | |
| Operating Income | $-613.2K | $-5M | $-6M | $-2M | $-3M | $-4M | $-469.5K | $-1M | $-2M | $-3M | $-3M | $-3M | $-3M | $-423.8K | $-144.9K | $-136.7K | |
| Interest Income | · | · | · | · | · | · | · | · | · | $114.3K | $105.8K | $381.9K | $204.3K | $64.2K | $3.7K | $857 | |
| Pretax Income | $-613.2K | $-5M | $-6M | $-2M | $-3M | $-4M | $-469.5K | · | $-2M | $-54.9K | · | · | · | $-359.6K | $-141.3K | $-135.8K | |
| Income Tax | $-25 | · | $850 | $13 | · | $1.6K | · | · | · | $21.1K | $19.5K | $80.6K | $0 | · | $0 | $0 | |
| Net Income | $-613.2K | $-5M | $-6M | $-2M | $-3M | $-4M | $-469.5K | $-1M | $-2M | $-3M | $-3M | $-3M | $-3M | $-359.6K | $-141.3K | $-242.5K | |
| EPS (Basic) | $-0.01 | $-0.13 | $-0.15 | $-0.06 | $-0.09 | $-0.11 | $-0.01 | $-0.03 | $-1.78 | $22.44 | $-8.13 | $-16.33 | $-34.33 | $-0.06 | $-0.02 | · | |
| EPS (Diluted) | $-0.01 | $-0.13 | $-0.15 | $-0.06 | $-0.09 | $-0.11 | $-0.01 | $-0.03 | $-1.78 | $22.44 | $-8.13 | $-16.33 | $-34.33 | $-0.06 | $-0.02 | · | |
| Shares (Basic) | -72,629,096 | 37,096,024 | 36,165,589 | 36,188,293 | 36,208,477 | 36,376,738 | 35,519,192 | 35,201,232 | 1,052,656 | -284,326 | 337,275 | 168,758 | 84,041 | 1,419,700 | 1,419,700 | · | |
| Shares (Diluted) | -72,629,096 | 37,096,024 | 36,165,589 | 36,188,293 | 36,208,477 | 36,376,738 | 35,519,192 | 35,201,232 | 1,052,656 | -284,326 | 337,275 | 168,758 | 84,041 | 1,419,700 | 1,419,700 | · | |
| EBITDA | · | $-5M | $-6M | $-2M | $-3M | · | $-469.5K | $-1M | $-2M | $-169.2K | $-149.7K | · | $-549.2K | $-423.8K | $-144.9K | · |
Bilanço 17
| Metrik | Eğilim | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q1 2024 | Q4 2024 | Q3 2024 | Q2 2023 | Q1 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 | Q2 2022 | Q1 2022 | Q4 2021 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $1M | $2M | $1M | $421.5K | $2M | $4M | $5M | $9M | $22M | $2M | $29.4K | $40.8K | $73.8K | $88.3K | $321.7K | $478.9K | |
| Prepaid Expense | $292.7K | $396.9K | $163.9K | $522.8K | $437.6K | $288.8K | $406.1K | $401.2K | $138.8K | $94.7K | $52.5K | $11.6K | $87.0K | $40.5K | $106.4K | $137.2K | |
| Current Assets | $2M | $2M | $1M | $944.3K | $2M | $4M | $9M | $9M | · | $3M | $81.9K | $52.4K | $160.8K | $128.8K | $428.1K | $616.0K | |
| Total Assets | $3M | $4M | $3M | $2M | $4M | $4M | $9M | $9M | $27M | $3M | $10M | $10M | $46M | $45M | $46M | $46M | |
| Accounts Payable | · | · | · | · | · | · | · | · | · | $437.8K | $375.0K | $329.2K | $206.5K | $106.4K | $6.0K | $3.0K | |
| Accrued Liabilities | · | · | · | · | · | · | $166.9K | · | · | · | · | · | · | · | · | · | |
| Current Liabilities | $14M | $13M | $9M | $4M | $3M | $180.7K | $138.5K | $398.7K | $17M | $10M | $1M | $1M | $735.8K | $154.6K | $30.2K | $73.2K | |
| Deferred Tax | · | · | · | · | · | · | · | · | · | $8.4K | $7.8K | $29.5K | · | · | · | · | |
| Other Non-current Liabilities | · | · | · | · | · | · | · | · | · | $12.7K | · | · | · | · | · | · | |
| Total Liabilities | $14M | $13M | $9M | $4M | $3M | $180.7K | $138.5K | $398.7K | $17M | $10M | $3M | $3M | $2M | $2M | $2M | $2M | |
| Common Stock | $3.8K | $3.8K | $3.8K | $3.7K | $3.7K | $3.7K | $3.7K | $3.5K | $3.5K | $98 | $142 | $142 | $142 | $142 | $142 | $142 | |
| Paid-in Capital | $27M | $27M | $26M | $25M | $24M | · | $24M | $24M | $24M | · | · | · | · | · | · | · | |
| Retained Earnings | $-37M | $-36M | $-32M | $-26M | $-23M | $-20M | $-16M | $-15M | $-14M | $-12M | $-3M | $-2M | $-2M | $-2M | $-1M | $-1M | |
| Treasury Stock | $598.4K | $598.4K | $598.4K | $598.4K | $504.9K | $354.4K | $84.1K | · | · | · | · | · | · | · | · | · | |
| Stockholders' Equity | $-10M | $-10M | $-6M | $-2M | $746.3K | $4M | $8M | $9M | $10M | $-12M | $-3M | $-2M | $-2M | $-2M | $-1M | $-1M | |
| Liabilities + Equity | $3M | $4M | $3M | $2M | $4M | $4M | $9M | $9M | $27M | $3M | $10M | $10M | $46M | $45M | $46M | $46M | |
| Shares Outstanding | · | 37,765,589 | 37,065,589 | 36,165,589 | · | 36,610,870 | 36,535,980 | 35,201,232 | 35,201,232 | 978,243 | 1,419,700 | 1,419,700 | 1,419,700 | 1,419,700 | 1,419,700 | 1,419,700 |
Nakit Akışı 8
| Metrik | Eğilim | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q1 2024 | Q4 2024 | Q3 2024 | Q2 2023 | Q1 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 | Q2 2022 | Q1 2022 | Q4 2021 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock-based Comp | $148.4K | $152.4K | $159.1K | $159.1K | · | · | · | · | $1M | $102.4K | $102.4K | $102.4K | $102.4K | · | · | · | |
| Deferred Tax | · | · | · | · | · | · | · | · | · | $598 | $-21.7K | · | · | · | · | · | |
| Operating Cash Flow | $-177.5K | $-727.3K | $1M | $-466.0K | $5M | $-4M | $-4M | $-11M | $-275.2K | $-43.2K | $-84.5K | $-108.2K | $-1M | $-233.4K | $-157.1K | $-293.3K | |
| Investing Cash Flow | · | · | · | · | · | $0 | $0 | $5M | $-112.3K | $-136.5K | $-235.7K | · | · | · | · | $0 | |
| Stock Issued | $0 | $1M | · | · | · | · | · | · | · | · | · | · | · | · | · | $0 | |
| Financing Cash Flow | $-64.8K | $1M | $1M | $-29.5K | $-14M | $-20M | $-84.1K | $-7M | $20M | $196.5K | $186.5K | $-36M | · | · | · | $0 | |
| Net Change in Cash | · | · | · | · | · | · | · | · | · | $5.3K | $-11.4K | $-33.0K | $-14.5K | $-233.4K | $-157.1K | $-293.3K | |
| Taxes Paid | $0 | $0 | $900 | $13 | $0 | $0 | · | · | · | · | · | · | · | · | · | · |
Kârlılık 3
| Metrik | Eğilim | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q1 2024 | Q4 2024 | Q3 2024 | Q2 2023 | Q1 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 | Q2 2022 | Q1 2022 | Q4 2021 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROA | · | -79.0% | -89.2% | -68.1% | -21.7% | · | -1.7% | -10.5% | -10.1% | -0.27% | -0.23% | · | -0.75% | -1.6% | -0.62% | · | |
| ROE | · | 715.8% | -375.4% | 388.0% | -62.4% | · | -14.4% | -32.8% | -49.6% | 3.5% | 3.5% | · | 24.2% | 47.7% | 24.6% | · | |
| ROIC | · | · | 91.0% | 114.9% | · | · | · | · | · | 8.3% | 8.5% | · | 27.7% | 28.1% | 12.6% | · |
Likidite ve Solventlik 2
| Metrik | Eğilim | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q1 2024 | Q4 2024 | Q3 2024 | Q2 2023 | Q1 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 | Q2 2022 | Q1 2022 | Q4 2021 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | · | 0.2 | 0.2 | 0.2 | 0.7 | · | 62.3 | 23.7 | · | 0.1 | 0.1 | · | 0.2 | 0.8 | 14.2 | · | |
| Quick Ratio | · | 0.1 | 0.1 | 0.1 | 0.6 | · | 34.1 | 22.7 | 1.3 | 0.0 | 0.0 | · | 0.1 | 0.6 | 10.7 | · |
Değerleme (TTM) 1
| Metrik | Eğilim | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q1 2024 | Q4 2024 | Q3 2024 | Q2 2023 | Q1 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 | Q2 2022 | Q1 2022 | Q4 2021 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income TTM | · | $-16M | $-14M | $-13M | · | · | · | $-3M | · | $-11M | · | · | · | $-611.9K | $-253.2K | · |
Finansal Tablolar Gelir tablosu, bilanço, nakit akışı — yıllık, son 5 yıl
Gelir Tablosu
| 2025-12-31 | 2024-12-31 | 2024-06-30 | 2023-06-30 | 2022-12-31 | |
|---|---|---|---|---|---|
| Net Gelir | $-13M | — | $-7M | $-11M | $-996.1K |
| Seyreltilmiş Hisse Başı Kâr | $-0.35 | — | $-0.27 | $-36.35 | — |
Bilanço
| 2025-12-31 | 2024-12-31 | 2024-06-30 | 2023-06-30 | 2022-12-31 | |
|---|---|---|---|---|---|
| Cari Oran | 0.1 | — | — | — | 0.0 |
| Cari Oran | 0.1 | — | — | — | 0.0 |
Metriklerim Kişisel izleme listeniz — Tam Temeller'den seçilen satırlar
📊
Sizin için önemli olan metrikleri seçin — yukarıdaki Tam Temeller'deki herhangi bir satırın yanındaki ➕ düğmesine tıklayın.
Seçiminiz kaydedildi ve tüm hisse senetlerinde sizinle birlikte gelir.